Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this randomized trial of 211 children and adolescents with moderate-to-severe psoriasis, response rates at 12 weeks were higher among patients treated with etanercept than among those receiving placebo (57% vs. 11%, P<0.001). Response was maintained during 24 weeks of open-label treatment. Three serious infections occurred in patients treated wi...
Alternative Titles
Full title
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_70211483
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_70211483
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa066886
